Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors
- PMID: 22977576
- PMCID: PMC3440723
- DOI: 10.3892/etm.2011.291
Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors
Abstract
Bronchopulmonary neuroendocrine tumors (BP-NETs) are separated into four subgroups: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC). The signaling pathway involving AKT/mammalian target of rapamycin (mTOR) is crucial to the regulation of cell growth, proliferation and survival, and is frequently activated in human cancers. Consequently, mTOR is considered an attractive target for anticancer agents. The present study aimed to evaluate the expression of phosphorylated AKT and mTOR in a series of BP-NETs, and to analyze the correlations with clinicopathological parameters. p-AKT and p-mTOR levels were determined by immunohistochemistry in a series of 210 BP-NETs, including 85 SCLCs, 17 LCNECs, 26 ACs, 75 TCs and 7 tumorlets. Higher p-AKT and p-mTOR expression levels were identified in the majority of tumorlets and carcinoids in comparison to the LCNECs (P=0.0001) and SCLCs (P=0.0002). Furthermore, a significant association was observed between p-mTOR expression and tumor size (T) in SCLCs (P=0.04) and LCNECs (P=0.03): T3-T4 tumors exhibited significantly lower p-mTOR expression compared to T1-T2 tumors. In conclusion, most of the BP-NETs examined in this study expressed p-AKT and p-mTOR, suggesting that the AKT/mTOR pathway plays an important role in these tumors. Additionally, our results confirm that low- to intermediate-grade tumors are more closely associated to each other than to high-grade tumors, despite sharing common classification and a common origin from neuroendocrine cells. These findings improve our knowledge of the biological characterization of these tumors and indicate new therapeutic opportunities for the treatment of BP-NETs.
Figures
Similar articles
-
Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.Biochim Biophys Acta. 2012 Dec;1826(2):255-71. doi: 10.1016/j.bbcan.2012.05.001. Epub 2012 May 10. Biochim Biophys Acta. 2012. PMID: 22579738 Review.
-
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.Endocr Relat Cancer. 2010 Oct 29;17(4):977-87. doi: 10.1677/ERC-10-0157. Print 2010 Dec. Endocr Relat Cancer. 2010. PMID: 20817788
-
Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.Am J Pathol. 1996 May;148(5):1531-41. Am J Pathol. 1996. PMID: 8623922 Free PMC article.
-
Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.Oncol Rep. 2011 Oct;26(4):931-7. doi: 10.3892/or.2011.1384. Epub 2011 Jul 11. Oncol Rep. 2011. PMID: 21750865
-
Bronchopulmonary neuroendocrine tumors.Cancer. 2008 Jul 1;113(1):5-21. doi: 10.1002/cncr.23542. Cancer. 2008. PMID: 18473355 Review.
Cited by
-
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance.Cancers (Basel). 2023 Feb 3;15(3):990. doi: 10.3390/cancers15030990. Cancers (Basel). 2023. PMID: 36765949 Free PMC article.
-
Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):153-163. doi: 10.21873/cgp.20073. Cancer Genomics Proteomics. 2018. PMID: 29496694 Free PMC article. Review.
-
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.J Clin Oncol. 2013 Sep 20;31(27):3418-25. doi: 10.1200/JCO.2012.46.6946. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980085 Free PMC article.
-
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.PLoS One. 2014 Feb 12;9(2):e88291. doi: 10.1371/journal.pone.0088291. eCollection 2014. PLoS One. 2014. PMID: 24533074 Free PMC article.
-
Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.Oncol Rep. 2012 Nov;28(5):1559-66. doi: 10.3892/or.2012.2017. Epub 2012 Sep 4. Oncol Rep. 2012. PMID: 22949056 Free PMC article.
References
-
- Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: 2004.
-
- Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–944. - PubMed
-
- Canessa PA, Santini D, Zanelli M, Capecchi V. Pulmonary tumourlets and microcarcinoids in bronchiectasis. Monaldi Arch Chest Dis. 1997;52:138–139. - PubMed
-
- Watanabe H, Kobayashi H, Honma K, Ohnishi Y, Iwafuchi M. Diffuse panbronchiolitis with multiple tumorlets. A quantitative study of the Kultschitzky cells and the clusters. Acta Pathol Jpn. 1985;35:1221–1231. - PubMed
-
- Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab. 2000;85:3425–3430. - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous